Biotech Daily covers the major announcements from ASX-listed biotech companies as well as the major research institutes and developments in government policy.
Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.
The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.
Subscriptions are $A940 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.
Subscribers include biotech directors and CEOs, major pharmaceutical companies, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
The website is best viewed with the Firefox browser.
Biotech Daily Top 40 With Market Capitalization At February 28, 2017
* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast
Nanosonics, Neuren and Volpara, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in.